The stock of FSD Pharma Inc (HUGE) has gone down by -10.43% for the week, with a -38.79% drop in the past month and a -48.17% drop in the past quarter. The volatility ratio for the week is 10.69%, and the volatility levels for the past 30 days are 9.44% for HUGE. The simple moving average for the past 20 days is -21.29% for HUGE’s stock, with a -56.55% simple moving average for the past 200 days.
Is It Worth Investing in FSD Pharma Inc (NASDAQ: HUGE) Right Now?
The 36-month beta value for HUGE is at 0.64. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for HUGE is 33.57M, and currently, shorts hold a 1.11% of that float. The average trading volume for HUGE on April 30, 2024 was 168.59K shares.
HUGE) stock’s latest price update
The stock price of FSD Pharma Inc (NASDAQ: HUGE) has dropped by -8.73 compared to previous close of 0.48. Despite this, the company has seen a fall of -10.43% in its stock price over the last five trading days. Accesswire reported 2023-08-15 that Targeting the Approximate $22 Billion Multiple Sclerosis Drug Treatment Market TORONTO, ON / ACCESSWIRE / August 15, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, is pleased to announce that its late breaking abstract about Phase 1 first-in-human data on Lucid-MS (Lucid-21-302) was selected for presentation at the upcoming MSMilan 2023 – 9th Joint ECTRIMS-ACTRIMS meeting scheduled for October 11-13, 2023. Lucid-MS is a potential drug candidate for multiple sclerosis (MS) targeting demyelination, the loss of the protective myelin sheath, in the central nervous system.
HUGE Trading at -38.44% from the 50-Day Moving Average
After a stumble in the market that brought HUGE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.93% of loss for the given period.
Volatility was left at 9.44%, however, over the last 30 days, the volatility rate increased by 10.69%, as shares sank -36.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -48.17% lower at present.
During the last 5 trading sessions, HUGE fell by -10.43%, which changed the moving average for the period of 200-days by -62.56% in comparison to the 20-day moving average, which settled at $0.5438. In addition, FSD Pharma Inc saw -52.38% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for HUGE
The total capital return value is set at -1.87. Equity return is now at value -83.28, with -65.24 for asset returns.
Based on FSD Pharma Inc (HUGE), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -32.19. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -35424.71.
Currently, EBITDA for the company is -17.38 million with net debt to EBITDA at 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.43.
Conclusion
In conclusion, FSD Pharma Inc (HUGE) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
